Sunshine Biopharma Inc. 8-K

What Happened
Sunshine Biopharma Inc. (SBFM) filed an 8-K (dated March 9, 2026) disclosing that on March 6, 2026 it entered an engagement agreement with Aegis Capital Corp. Under the agreement Aegis will act as the Company’s warrant solicitation agent on a “best efforts” basis to induce exercise of the Company’s outstanding warrants.

Key Details

• Engagement date: March 6, 2026; 8-K filed March 9, 2026.
• Term: three months.
• Fee: Aegis will receive 10% of the gross proceeds from any warrants exercised during the engagement term.
• Company will also reimburse certain Aegis expenses; Aegis’s role is on a “best efforts” (not guaranteed) basis.

Why It Matters
If warrant holders exercise, the company will receive cash proceeds but existing shareholders could face dilution because exercises typically convert warrants into shares. The 10% fee payable to Aegis reduces the net cash Sunshine Biopharma receives from any exercises. The three‑month, best‑efforts solicitation indicates the company is actively seeking near-term warrant conversions, which could affect shares outstanding and the company’s cash position.